Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.
"The value of the Brazilian breast cancer drug market in 2009 ($424 million) rivals those in some major pharmaceutical markets (United Kingdom, Japan) and greatly exceeds breast cancer drug sales in other emerging markets (China, India, Russia)," stated Decision Resources' Therapeutic Area Director Kate Hohenberg. "A well-established public healthcare system that pays the cost of drug therapy for eligible patients and a small but lucrative pool of privately insured patients support Brazil's sizeable breast cancer drug market."
The new Emerging Markets report entitled Breast Cancer in Brazil also finds that given the drawbacks and limitations of current treatments and Brazilian physicians' enthusiasm for novel approaches in hard-to-treat patient segments (e.g., triple-negative breast cancer), emerging breast cancer therapies will be well received in Brazil. Two novel agents -- Roche's trastuzumab-DM1 and Sanofi -Aventis's BSI-201 -- are expected to launch in Brazil towards the end of 2014.
"By the end of our five-year forecast period (2009 - 2014), we expect two novel breast cancer agents to launch in Brazil -- Roche's trastuzumab-DM1 and Sanofi -Aventis's BSI-201. These launches will be facilitated by the low regulatory hurdle (additional domestic clinical trials are not required) and physicians' receptivity to new therapies for underserved segments of the breast cancer market," added Ms. Hohenberg.
The new reports features extensive primary research of physicians and epidemiology study, with analysis of trends in major Brazilian cities -- Rio de Janeiro, Sao Paulo, Brasilia, Belo Horizonte, Curitiba and Salvador -- and the country overall.
About Emerging Markets Reports
Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Christopher Comfort Decision Resources 781-296-2597 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Christopher Comfort, Decision Resources, +1-781-296-2597,
Web Site: http://www.decisionresources.com/